

Anca Prica

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/297497/publications.pdf>

Version: 2024-02-01

67
papers

391
citations

840776

11
h-index

839539

18
g-index

67
all docs

67
docs citations

67
times ranked

654
citing authors

#	ARTICLE	IF	CITATIONS
1	Fixed duration <i>vs.</i> prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 23-30.	3.0	0
2	The Use of Virtual Care in Patients with Hematologic Malignancies: A Scoping Review. Current Oncology, 2022, 29, 892-900.	2.2	9
3	Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. American Journal of Hematology, 2022, 97, 583-591.	4.1	7
4	Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor â€“ a retrospective, single center study. Leukemia and Lymphoma, 2022, , 1-8.	1.3	1
5	Frailty in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Receiving Curative-Intent Therapy: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 635-642.e9.	4.9	6
6	Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials. Clinical Trials, 2021, 18, 500-504.	1.6	2
7	Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy. Bone Marrow Transplantation, 2021, 56, 2400-2409.	2.4	7
8	A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 766-774.	0.4	4
9	Association of Thoracic Computed Tomographic Measurements and Outcomes in Patients with Hematologic Malignancies Requiring Mechanical Ventilation. Annals of the American Thoracic Society, 2021, 18, 1219-1226.	3.2	4
10	Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. Journal of Clinical Oncology, 2021, 39, 3453-3462.	1.6	32
11	Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma. Journal of Nuclear Medicine, 2021, , jnumed.121.262324.	5.0	2
12	First Line B+R in Elderly Patients with Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma: A Real-World Experience. Blood, 2021, 138, 4519-4519.	1.4	0
13	Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size. Blood, 2021, 138, 460-460.	1.4	1
14	The Use of Virtual Care in Patients with Hematologic Malignancies - a Scoping Review. Blood, 2021, 138, 1933-1933.	1.4	0
15	Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume. Blood, 2021, 138, 1383-1383.	1.4	0
16	Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial. Blood, 2021, 138, 4076-4076.	1.4	0
17	Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma. Blood, 2021, 138, 1837-1837.	1.4	1
18	Are Novel Therapies Worth the Cost for Young Patients?: A Cost-Effectiveness Analysis of Frontline Therapies with or without Radiation for Early-Stage Unfavourable Hodgkin Lymphoma. Blood, 2021, 138, 662-662.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Virtual Care during the COVID-19 Pandemic Among Patients with Hematologic Malignancies - a Princess Margaret Cancer Centre Experience. <i>Blood</i> , 2021, 138, 838-838.	1.4	0
20	Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma. <i>Blood</i> , 2021, 138, 655-655.	1.4	0
21	Outcomes of Patients with Indolent Lymphoma Treated with Bendamustine Plus Rituximab Compared to Rituximab Plus CVP or CHOP Chemoimmunotherapy in Ontario. <i>Blood</i> , 2021, 138, 3546-3546.	1.4	0
22	Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation. <i>Blood</i> , 2021, 138, 3055-3055.	1.4	2
23	Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras. <i>Bone Marrow Transplantation</i> , 2020, 55, 578-585.	2.4	17
24	Light Chain Crystal Podocytopathy in a Patient With Systemic Indolent B-Cell Lymphoma. <i>Kidney International Reports</i> , 2020, 5, 373-376.	0.8	1
25	Impact of 18F-fluorodeoxyglucose PET/CT in the management of patients with plasma cell disorders. <i>Nuclear Medicine Communications</i> , 2020, 41, 34-39.	1.1	2
26	A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. <i>Blood Advances</i> , 2020, 4, 5762-5771.	5.2	3
27	Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2153-2160.	1.3	1
28	Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study. <i>Lancet Haematology</i> , 2020, 7, e146-e156.	4.6	19
29	A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930). <i>Blood</i> , 2020, 136, 5-6.	1.4	12
30	RBC-Enhance: A Randomized Pilot Feasibility Trial of Red Cell Transfusion Thresholds in Myelodysplastic Syndromes. <i>Blood</i> , 2020, 136, 3-4.	1.4	11
31	Frailty Is Associated with Increased One-Year Mortality in Patients with Newly Diagnosed Diffuse Large-B-Cell Lymphoma: A Population-Based Study. <i>Blood</i> , 2020, 136, 34-37.	1.4	1
32	A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 27-30.	1.4	1
33	SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 23-24.	1.4	9
34	Significance of treatment response when managing patients with primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 349-357.	1.3	3
35	Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2019, 60, 573-582.	1.3	11
36	Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer—the 5C study: a study protocol for a randomised controlled phase III trial. <i>BMJ Open</i> , 2019, 9, e024485.	1.9	23

#	ARTICLE	IF	CITATIONS
37	Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2576-2579.	1.3	0
38	Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry. <i>Radiology</i> , 2019, 290, 488-495.	7.3	22
39	Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mrcn-001 Study. <i>Blood</i> , 2019, 134, 4570-4570.	1.4	1
40	Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?. <i>Blood</i> , 2019, 134, 5704-5704.	1.4	0
41	The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of Overall Survival. <i>Blood</i> , 2019, 134, 1559-1559.	1.4	0
42	Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma. <i>Blood</i> , 2019, 134, 2027-2027.	1.4	0
43	Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 225-234.	0.4	7
44	Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma. <i>Blood</i> , 2018, 132, 4610-4610.	1.4	0
45	Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2248-2248.	1.4	1
46	Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience. <i>Blood</i> , 2018, 132, 4614-4614.	1.4	0
47	Functional Predictors of Chemotherapy Toxicity in Elderly Lymphoma Patients: A Prospective Pilot Study. <i>Blood</i> , 2018, 132, 4843-4843.	1.4	1
48	Fertility preservation in post-pubescent female cancer patients: A practical guideline for clinicians. <i>Molecular and Clinical Oncology</i> , 2017, 8, 153-158.	1.0	10
49	Financial Impact of Cancer Drug Wastage and Potential Cost Savings From Mitigation Strategies. <i>Journal of Oncology Practice</i> , 2017, 13, e646-e652.	2.5	19
50	Recurrent Body Rash Warranted Second Desensitization With Acyclovir in a Myeloma Patient: A Case Report. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 725-728.	1.2	4
51	Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 387-394.	0.4	11
52	ABVD Versus Combination Baseline Beacopp/Escalated Beacopp in the Treatment of Newly Diagnosed Advanced-Stage Hodgkin Lymphoma: A Decision Analysis. <i>Blood</i> , 2016, 128, 1183-1183.	1.4	1
53	Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting. <i>Blood</i> , 2016, 128, 2137-2137.	1.4	3
54	Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Heavy/light Chain (HLC) Ratio Assessments. <i>Blood</i> , 2016, 128, 4632-4632.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant. Blood, 2016, 128, 3457-3457.	1.4	0
56	Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab Naïve Patients?. Blood, 2016, 128, 1795-1795.	1.4	0
57	Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model. Blood, 2016, 128, 1184-1184.	1.4	0
58	Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis. Cancer, 2015, 121, 2637-2645.	4.1	20
59	Clinical Reasoning: A 66-year-old man with recurrent multi-territory infarcts. Neurology, 2015, 84, e195-201.	1.1	0
60	Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome. British Journal of Haematology, 2015, 169, 461-461.	2.5	17
61	Myelodysplastic Syndrome Successfully Treated With Adalimumab. Journal of Clinical Oncology, 2015, 33, e4-e6.	1.6	5
62	Enteropathy-Associated T-Cell Lymphoma: A Single Centre Experience. Blood, 2015, 126, 5057-5057.	1.4	0
63	Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience. Blood, 2015, 126, 1842-1842.	1.4	0
64	Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience. Blood, 2015, 126, 5361-5361.	1.4	0
65	Safety and efficacy of thrombopoietin receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. British Journal of Haematology, 2014, 167, 626-638.	2.5	50
66	Rapidity and Quality of Response to Steroid-Based Induction Therapy, Without the Addition of Novel Agents, Does Not Affect Post Transplant Outcomes in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 25-31.	0.4	5
67	Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis. British Journal of Haematology, 2012, 158, 600-607.	2.5	20